Exact Sciences (NASDAQ: EXAS)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Exact Sciences Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Exact Sciences Company Info
An applied genomics company that develops proprietary DNA-based technologies for use in the detection of cancer.
News & Analysis
Wood's ARK Innovation ETF is rebounding nicely.
Investors are attracted to its leading position in the market for early cancer detection, but the persistent losses its been reporting are enough to make anyone nervous.
Here are the five best biotech ETFs to invest in right now.
The company's fast-growing business has loads of potential, but it may not be suitable for all investors.
Here's how to get tech exposure without the single-stock risk.
Investors are reacting positively to the company's Q3 update.
These companies aren't handling the downturn well, but they can turn things around.
Investment bank analysts think these stocks will shoot through the roof once the rest of the market sees them in the same light.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 01/29/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
EXAS earnings call for the period ending September 30, 2022.
EXAS earnings call for the period ending June 30, 2022.
EXAS earnings call for the period ending March 31, 2022.
EXAS earnings call for the period ending December 31, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.